Actinobac Biomed, Inc. is a biopharmaceutical company that focuses on the development of pharmaceutical technologies based upon the natural biologic agent leukotoxin (Leukothera™), which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells.

Categories

Industry Biomedical
Sub-industry
Focus Areas
Focus Areas - detailed

University

University Rutgers
Principal Investigator Scott Kachlany, Ph.D. - Center for Oral Infectious Diseases, School of Dental Medicine

Company

Web http://actinobac.com/
Address
Phone
Fax
Email

Timeline

2009 - Founded



No files attached to this page.

Add a New Comment